Genmab A-S

Genmab A-S

Yahoo Finance • 29 days ago

Could Genmab (GMAB) Stock Win as Royalty Growth Fuels a New Earnings Cycle?

Genmab A/S (NASDAQ:GMAB) boosted its full-year 2026 revenue guidance to a range of $4.325 billion to $4.525 billion, up from its previous outlook of $4.065 billion to $4.395 billion. The upward revision underscores the strong commercial mo... Full story

Yahoo Finance • last month

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evalu... Full story

Yahoo Finance • last month

Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Mariott International, Merck, Novo Nordisk, Okta, and More

Pre-Market Stock Futures: Futures are trading modestly higher as we have arrived at the day everyone on Wall Street has circled on their calendars. The July consumer price index will be released at 8:30 AM EDT, and the producer price inde... Full story

Yahoo Finance • 2 months ago

Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook

This article first appeared on GuruFocus. Genmab (NASDAQ:GMAB), a biotechnology company focused on antibody medicines, delivered another quarter that reminded investors why royalty businesses can be so powerful. First-half revenue climbed... Full story

Yahoo Finance • 2 months ago

Genmab (GMAB) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 12:00 p.m. ET CALL PARTICIPANTS Chief Executive Officer - Jan van de WinkelChief Financial Officer - Anthony PaganoChief Commercial Officer - Brad BaileyChief Medical Office... Full story

Yahoo Finance • 2 months ago

AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Genmab and AbbVie (ABBV) recently clarified that the U.S. portion of the Phase 3 EPCORE DLBCL-1... Full story

Yahoo Finance • 2 months ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Genmab A/S Media Release COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; July 23, 2026 Genmab and AbbVie clarify overall survival (OS) was the sole U.S. primary endpoint in the Phase 3 EPCORE® DLBCL-1 trial and was not met Genmab A/S(Nasd... Full story

Yahoo Finance • 2 months ago

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Altria, Circle Internet, Coreweave, Digital Ocean, IBM, Keel Infrastructure, Nebius Group, Trimble, Vornado Realty, and More

Quick Read 88% of early S&P 500 reporters beat Q2 estimates, crushing the 76% historical average and fueling Tuesday's broad market rally. COIN rocketed 11% on Bessent's Digital Asset Market Clarity Act news, while CRWV was upgraded to Bu... Full story

Yahoo Finance • 2 months ago

Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight

DelveInsight Business Research LLP The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted th... Full story

Yahoo Finance • 2 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026

Genmab A/S Company Announcement Net sales of DARZALEX® in the second quarter of 2026 totaled USD 4,207 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN,... Full story

Yahoo Finance • 2 months ago

AbbVie extends slide to a seventh straight session

AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]) declines 1.30% to $244.78 in Tuesday afternoon trading, on track for its seventh straight session of losses. Over the past six trading sessions, the stock has declined 5.1%, compared wi... Full story

Yahoo Finance • 3 months ago

Is Genmab A/S (GMAB) Stock Undervalued After Positive Epkinly DLBCL Trial Results?

We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks on our list. TheFly reported on July 2 that H.C. Wainwright analyst Raghuram Selvaraju incre... Full story

Yahoo Finance • 3 months ago

William Blair updates conviction list: Oracle in, Meta out and more

[Technology background image, graph, displaying analytical data about stock trading.] Donny DBM William Blair added Oracle (ORCL [https://seekingalpha.com/symbol/ORCL]), American Express (AXP [https://seekingalpha.com/symbol/AXP]), Ecolab... Full story

Yahoo Finance • 3 months ago

AbbVie touts phase 3 results for Epkinly in 2L large B-cell lymphoma

[Diffuse large B-cell lymphoma (DLBCL) - semicloseup view 3d illustration] Nemes Laszlo/iStock via Getty Images * AbbVie (ABBV [https://seekingalpha.com/symbol/ABBV]) said that its experimental T-cell engaging bispecific antibody Epkinl... Full story

Yahoo Finance • 3 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption righ... Full story

Yahoo Finance • 3 months ago

Genmab’s EPCORE Data Deepens Lymphoma Profile As Investors Weigh Upside

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Genmab (CPSE:GMAB) released new subgroup data from its pivotal Phase 3 EPCORE FL-1 trial of epco... Full story

Yahoo Finance • 3 months ago

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release COPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated early responses in elderly patients with newly diagnosed diffuse large B-cell lymp... Full story

Yahoo Finance • 3 months ago

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

Media Release COPENHAGEN, Denmark; June 11, 2026 Findings from a post-hoc subgroup analysis of the Phase 3 EPCORE® FL-1 trial reinforce fixed-duration epcoritamab in combination with rituximab and lenalidomide (R2 ) data across subgroups... Full story

Yahoo Finance • 4 months ago

Truist Assigns Buy Rating to Genmab (GMAB)

Genmab A/S (NASDAQ:GMAB) is one of the 10 best large cap stocks under $30 with highest upside potential. On May 27, coverage of Genmab A/S (NASDAQ:GMAB) was resumed by Truist analyst Gregory Renza. The analyst reduced the price target fro... Full story

Yahoo Finance • 4 months ago

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Company Announcement COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the tr... Full story